A Phase III Multi-National, Multi-Centre, Open Label, 52 Week Safety Study to Assess the Safety of Chronic Therapy With the Humanised AntipTNF PEG Conjugate CDP870 400 mg sc, Dosed 4 weekly to Week 48, in the Treatment of Patients With Active Crohns

  • De Villiers, Willem (PI)

Grants and Contracts Details

Effective start/end date1/15/0412/31/06